Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALT, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Licensed seasonal influenza vaccine | Influenza | Phase 4 · NCT03163342 | Completed |
| Pemvidutide | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 3 · NCT07795164 | Recruiting |
| HepTcell | Hepatitis B, Chronic | Phase 2 · NCT04684914 | Terminated |
| NasoVAX | Influenza | Phase 2 · NCT03232567 | Completed |
| AdCOVID | Healthy Volunteers | Phase 1 · NCT04679909 | Completed |
| Atorvastatin | NASH - Nonalcoholic Steatohepatitis | Phase 1 · NCT04972396 | Completed |
| BioThrax | Healthy Volunteers | Phase 1 · NCT03352466 | Completed |
| Ethinyl Estradiol | NASH - Nonalcoholic Steatohepatitis | Phase 1 · NCT04972396 | Completed |
| FP-02.2 Vaccine | Hepatitis B | Phase 1 · NCT02496897 | Completed |
| Metformin | NASH - Nonalcoholic Steatohepatitis | Phase 1 · NCT04972396 | Completed |
| NasoShield | Healthy Volunteers | Phase 1 · NCT04415749 | Completed |
| Pandemic Influenza Vaccine | Influenza A Subtype H5N1 Infection | Phase 1 · NCT00755703 | Completed |
| Warfarin | NASH - Nonalcoholic Steatohepatitis | Phase 1 · NCT04972396 | Completed |
| Subjects were administered NasoVAX high dose | Influenza | N/A · NCT03760549 | Completed |
Also used in these trials (approved or third-party drugs, not ALT's own candidates): IL-2 Recombinant Fusion Protein ALT-801, Digoxin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALT holds $479.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $31M/quarter from operations, an estimated runway of 46.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 45 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALT files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | Institution (13G, 5%+) | 19,417,221 | 9.98% | 2026-04-23 |
| VIKING GLOBAL INVESTORS LP | 5%+ holder (13G) | 13,400,000 | 6.89% | 2026-04-24 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 13,000,000 | 6.68% | 2026-04-24 |
| Vipin K Garg Director · +26,775 options |
Insider | 424,519 | 0.22% | 2026-01-30 |
| M Scot Roberts Chief Scientific Officer · +318,100 options |
Insider | 113,699 | 0.06% | 2026-07-31 |
| Jerome Benedict Durso President and CEO, Director · +2.46M options |
Insider | 93,200 | 0.05% | 2026-11-13 |
| Gregory L Weaver Chief Financial Officer · +463,300 options |
Insider | 73,005 | 0.04% | 2026-11-13 |
| Raymond M Jordt Chief Business Officer · +47,550 options |
Insider | 70,107 | 0.04% | 2026-01-31 |
| Wayne Pisano Director · +48,800 options |
Insider | 58,800 | 0.03% | 2026-11-13 |
| Christophe Arbet-Engels Chief Medical Officer · +562,500 options |
Insider | 24,821 | 0.01% | 2026-10-01 |
| John Gill Director · +48,800 options |
Insider | 21,700 | 0.01% | 2026-04-06 |
| Linda M Richardson Chief Commercial Officer · +72,000 options |
Insider | 17,174 | 0.01% | 2026-09-16 |
Share count 194,589,451 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALT and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →